CD86 and neoplasm: Preclinical studies using murine tumor models have indicated an increase in the number of activated dendritic cells (APCs) as evidenced by increased expression of MHC class II, CD80, and CD86, as well as increased levels of IL-12 and IFNγ in the tumor microenvironment post HIFU [20–22].